Abstract
Breast cancer is a prominent cause of mortality in women worldwide, with about 2/3rd cases linked to hormone mediated malignancy itself. A hormone receptor positive breast cancer represents cells showing rigorous proliferation upon hormonal exposure. BRCA1 is the predominant marker gene responsible for estrogen regulation. However increased exposure to estrogen is not the sole cause for this abnormality as there is no significant alteration reported in breast tissue estrogen levels. Iron metabolism has also been shown to be frequently altered in breast cancer with considerably higher iron in post menstrual women. In fact estrogen and iron have been implicated to exert synergistic effects on cellular proliferation in BRCA1 linked hormone responsive breast cancer. Thus establishing a link between estrogen and iron metabolism has a great prognostic value in predicting clinical outcome in BRCA1 linked hormone responsive breast cancer patients. Since the time immemorial Iron chelators have been implicated in combating iron dysregulation especially in breast cancer. We summarize here in this review the recent advancements in the area of iron chelation therapy delineating the role of iron in hormone receptor positive Breast cancer.
Keywords: Breast cancer, estrogen, hormone, iron chelation, metabolism.
Current Pharmaceutical Biotechnology
Title:Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects
Volume: 15 Issue: 12
Author(s): Abdulrazzaq N. Zghair, Rohit Sharma and Anil K. Sharma
Affiliation:
Keywords: Breast cancer, estrogen, hormone, iron chelation, metabolism.
Abstract: Breast cancer is a prominent cause of mortality in women worldwide, with about 2/3rd cases linked to hormone mediated malignancy itself. A hormone receptor positive breast cancer represents cells showing rigorous proliferation upon hormonal exposure. BRCA1 is the predominant marker gene responsible for estrogen regulation. However increased exposure to estrogen is not the sole cause for this abnormality as there is no significant alteration reported in breast tissue estrogen levels. Iron metabolism has also been shown to be frequently altered in breast cancer with considerably higher iron in post menstrual women. In fact estrogen and iron have been implicated to exert synergistic effects on cellular proliferation in BRCA1 linked hormone responsive breast cancer. Thus establishing a link between estrogen and iron metabolism has a great prognostic value in predicting clinical outcome in BRCA1 linked hormone responsive breast cancer patients. Since the time immemorial Iron chelators have been implicated in combating iron dysregulation especially in breast cancer. We summarize here in this review the recent advancements in the area of iron chelation therapy delineating the role of iron in hormone receptor positive Breast cancer.
Export Options
About this article
Cite this article as:
Zghair N. Abdulrazzaq, Sharma Rohit and Sharma K. Anil, Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects, Current Pharmaceutical Biotechnology 2014; 15 (12) . https://dx.doi.org/10.2174/1389201015666141126120725
DOI https://dx.doi.org/10.2174/1389201015666141126120725 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Tricyclic Structures in Medicinal Chemistry: An Overview of their Recent Uses in Non-CNS Pathologies
Mini-Reviews in Medicinal Chemistry Epigenetics in Clinical Management of Children and Adolescents with Brain Tumors
Current Cancer Drug Targets The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB)
Current Pharmaceutical Biotechnology Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer
Current Gene Therapy Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Current Pharmaceutical Biotechnology Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Dendrimer-Curcumin Conjugate: A Water Soluble and Effective Cytotoxic Agent Against Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
Current Cancer Drug Targets A Comparative Study of Glucose and Fructose in the Development of Sarcoma 180 in Mice
Letters in Organic Chemistry Targeting TNF-Alpha in HIV-1 Infection
Current Drug Targets SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging A Pilot Study for Investigation of Plasma Amino Acid Profile in Neurofibromatosis Type 1 Patients
Combinatorial Chemistry & High Throughput Screening Bis (Isothiocyanatomethyl) Benzene, A Plant Derived Anti-Neoplastic Compound: Purified from Moringa Oleifera Leaf Extract
Anti-Cancer Agents in Medicinal Chemistry Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Trichothecin from Endophytic Fungus Trichothecium sp. and its Anticancer Effect on Murine Melanoma and Breast Cancer Cell Lines
Current Biochemical Engineering (Discontinued) Caveolin Involvement and Modulation in Breast Cancer
Mini-Reviews in Medicinal Chemistry